Article Text

Download PDFPDF
Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report
  1. N. NAGAI*,
  2. E. HIRATA*,
  3. T. KUSUDA*,
  4. K. MUKAI*,
  5. K. ARIHIRO and
  6. K. OHAMA*
  1. *Department of Obstetrics and Gynecology, Hiroshima University Graduate School of Biological Sciences, Hiroshima, Japan
  2. Department of Pathology, Hiroshima University Hospital, Hiroshima, Japan
  1. Address correspondence and reprint requests to: Nobutaka Nagai, MD, PhD, Department of Obstetrics and Gynecology, Hiroshima University Graduate School of Biological Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Email: nnagai{at}hiroshima-u.ac.jp

Abstract

Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported. We report a patient with VGPA stage IIA responding to neoadjuvant chemotherapy with docetaxel (60 mg/m2 as an intravenous infusion) and cisplatin (70 mg/m2 as an intra-arterial infusion). At 3 weeks after completing one course of this regimen, the tumor size was reduced from 5.3 × 4.0 cm to 2.0 × 2.0 cm (81.1% reduction), revealed by computed tomography. Accordingly, the patient underwent radical hysterectomy, and there have been no signs of recurrence. Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma

  • docetaxel and cisplatin
  • neoadjuvant chemotherapy
  • villoglandular papillary adenocarcinoma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.